Reason: Filed for bankruptcy
Source: https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/biolase-voluntarily-initiates-chapter-11-proceedings-926432
P/E ratio for Biolase (BIOL)
P/E ratio on July 30, 2025 (TTM): -0.0011
According to Biolase 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.00110803. At the end of 2022 the company had a P/E ratio of -0.1580.
P/E ratio history for Biolase from 2001 to 2024
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -0.1580 | -95.48% |
| 2021 | -3.49 | 394.8% |
| 2020 | -0.7063 | 0.95% |
| 2019 | -0.6996 | -25.8% |
| 2018 | -0.9429 | |
| 2016 | -5.19 | 109.6% |
| 2015 | -2.47 | -56.73% |
| 2014 | -5.72 | -31.59% |
| 2013 | -8.36 | -54.48% |
| 2012 | -18.4 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Align Technology
ALGN | 37.5 | -3,383,419.95% | 🇺🇸 USA |
 Dentsply Sirona
XRAY | -3.55 | 320,149.45% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.